EA201590296A1 - Дейтерированный ибрутиниб - Google Patents

Дейтерированный ибрутиниб

Info

Publication number
EA201590296A1
EA201590296A1 EA201590296A EA201590296A EA201590296A1 EA 201590296 A1 EA201590296 A1 EA 201590296A1 EA 201590296 A EA201590296 A EA 201590296A EA 201590296 A EA201590296 A EA 201590296A EA 201590296 A1 EA201590296 A1 EA 201590296A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ibrutinib
deuterated
formula
deuterated ibrutinib
compound
Prior art date
Application number
EA201590296A
Other languages
English (en)
Inventor
Роджер Д. Тунг
Адам Дж. Морган
Original Assignee
Консерт Фармасьютикалс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Консерт Фармасьютикалс Инк. filed Critical Консерт Фармасьютикалс Инк.
Publication of EA201590296A1 publication Critical patent/EA201590296A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

Настоящее изобретение в одном варианте осуществления относится к соединению формулы Iили его фармацевтически приемлемой соли, при этом переменные, указанные в формуле I, определены в описании заявки.
EA201590296A 2012-07-30 2013-07-30 Дейтерированный ибрутиниб EA201590296A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261677307P 2012-07-30 2012-07-30
PCT/US2013/052721 WO2014022390A1 (en) 2012-07-30 2013-07-30 Deuterated ibrutinib

Publications (1)

Publication Number Publication Date
EA201590296A1 true EA201590296A1 (ru) 2015-07-30

Family

ID=48917743

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590296A EA201590296A1 (ru) 2012-07-30 2013-07-30 Дейтерированный ибрутиниб

Country Status (13)

Country Link
US (2) US9422295B2 (ru)
EP (1) EP2882751B1 (ru)
JP (1) JP6261580B2 (ru)
KR (1) KR20150038486A (ru)
CN (1) CN104507946A (ru)
AU (1) AU2013296627C9 (ru)
BR (1) BR112015001839A2 (ru)
CA (1) CA2879400A1 (ru)
EA (1) EA201590296A1 (ru)
ES (1) ES2682043T3 (ru)
IN (1) IN2015DN00598A (ru)
MX (1) MX2015001246A (ru)
WO (1) WO2014022390A1 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9422295B2 (en) 2012-07-30 2016-08-23 Concert Pharmaceuticals, Inc. Deuterated ibrutinib
CN105017256A (zh) * 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
CN103965201A (zh) * 2014-04-30 2014-08-06 淮海工学院 一种合成依鲁替尼中间体4-氨基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-d]嘧啶的方法
CN104945404B (zh) * 2014-06-25 2018-09-14 广东东阳光药业有限公司 一种n-丙烯羰基哌啶衍生物的制备方法
MA41350A (fr) * 2015-01-14 2017-11-21 Janssen Pharmaceutica Nv Synthèse d'un inhibiteur de la tyrosine kinase de bruton
CN107207519B (zh) * 2015-02-12 2019-11-08 正大天晴药业集团股份有限公司 伊布替尼的制备方法
WO2016132383A1 (en) * 2015-02-18 2016-08-25 Mylan Laboratories Limited Process for the preparation of ibrutinib
CN106146508A (zh) * 2015-03-19 2016-11-23 浙江导明医药科技有限公司 优化的联合用药及其治疗癌症和自身免疫疾病的用途
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
WO2016151438A1 (en) * 2015-03-20 2016-09-29 Sun Pharmaceutical Industries Limited A process for the preparation of ibrutinib
MX2018013347A (es) * 2016-05-04 2019-09-02 Concert Pharmaceuticals Inc Tratamiento de trastornos de pérdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
WO2018187187A1 (en) * 2017-04-04 2018-10-11 Combiphos Catalysts, Inc. Deuterated (s)-2-(4-(piperidin-3-yl)phenyl)-2h-indazole-7-carboxamide
TW201922256A (zh) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
CN109988175A (zh) * 2019-04-28 2019-07-09 梯尔希（南京）药物研发有限公司 一种依鲁替尼-d5的制备方法
CN112876484B (zh) * 2020-08-31 2022-06-28 绍兴舜邦医药科技有限公司 一种氘代依鲁替尼的制备方法
CN112125913A (zh) * 2020-10-29 2020-12-25 瑞阳制药股份有限公司 高纯度伊布替尼的合成方法
WO2023284765A1 (zh) * 2021-07-16 2023-01-19 深圳市塔吉瑞生物医药有限公司 取代的吡唑类化合物及包含该化合物的组合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
WO1995026325A2 (en) 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
EP1104760B1 (en) 1999-12-03 2003-03-12 Pfizer Products Inc. Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
DE10155018A1 (de) * 2001-11-07 2003-07-10 Berolina Drug Dev Ab Svedala Deuterierte Pyrazolopyrimidinone sowie diese Verbindungen enthaltende Arzneimittel
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
CA2624179A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
US20080103122A1 (en) 2006-09-05 2008-05-01 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
HUE031334T2 (hu) * 2006-09-22 2017-07-28 Pharmacyclics Llc Bruton-tirozinkináz inhibitorok
WO2013118150A1 (en) 2012-02-08 2013-08-15 Council Of Scientific & Industrial Research "electronically conducting carbon and carbon-based material by pyrolysis of dead leaves and other similar natural waste"
US9422295B2 (en) * 2012-07-30 2016-08-23 Concert Pharmaceuticals, Inc. Deuterated ibrutinib

Also Published As

Publication number Publication date
CN104507946A (zh) 2015-04-08
CA2879400A1 (en) 2014-02-06
AU2013296627C1 (en) 2016-12-15
US20150210699A1 (en) 2015-07-30
US9422295B2 (en) 2016-08-23
JP2015528020A (ja) 2015-09-24
US20170015670A1 (en) 2017-01-19
MX2015001246A (es) 2015-04-10
AU2013296627B2 (en) 2016-07-14
US9777009B2 (en) 2017-10-03
ES2682043T3 (es) 2018-09-18
KR20150038486A (ko) 2015-04-08
IN2015DN00598A (ru) 2015-06-26
AU2013296627A1 (en) 2015-02-05
EP2882751A1 (en) 2015-06-17
WO2014022390A1 (en) 2014-02-06
BR112015001839A2 (pt) 2017-07-04
EP2882751B1 (en) 2018-06-27
AU2013296627C9 (en) 2018-03-22
JP6261580B2 (ja) 2018-01-17

Similar Documents

Publication Publication Date Title
EA201590296A1 (ru) Дейтерированный ибрутиниб
EA201590321A1 (ru) Дейтерированный барицитиниб
EA201390081A1 (ru) Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
UY34156A (es) Compuestos inhibidores de metaloenzimas
UA113643C2 (xx) N-цикліламіди як нематоциди
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
UY34654A (es) Inhibidores de la beta-secretasa
EA201590951A1 (ru) Дигидропиразольные модуляторы gpr40
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
UY34034A (es) Triazolopiridinas
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
IN2012DE00621A (ru)
EA201590954A1 (ru) Дигидропиразольные модуляторы gpr40
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40
EA201690894A1 (ru) Феноксиэтилы
UY34006A (es) Imidazopiridazinas
CR20150211A (es) Compuestos diméricos
TR201821285T4 (tr) CCR3 antagonisti içeren farmasötik formülasyonlar.
IN2012DE00620A (ru)
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
MX2015008829A (es) Momelotinib deuterado.
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
IN2014DN10669A (ru)